946-76-9

Basic information

• Product Name: carbonylcyanide 4-chlorophenylhydrazone
• Synonyms: carbonylcyanide 4-chlorophenylhydrazone
• CAS NO: 946-76-9
• Molecular Formula: C₉H₅ClN₄
• Molecular Weight: 0
• Mol File: 946-76-9.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 320.2°Cat760mmHg
• Flash Point: 147.5°C
• Appearance: /
• Density: 1.26g/cm³
• Vapor Pressure: 0.000322mmHg at 25°C
• Refractive Index: 1.611
• CAS DataBase Reference: carbonylcyanide 4-chlorophenylhydrazone(CAS DataBase Reference)
• NIST Chemistry Reference: carbonylcyanide 4-chlorophenylhydrazone(946-76-9)
• EPA Substance Registry System: carbonylcyanide 4-chlorophenylhydrazone(946-76-9)

Safety Data

• Hazardous Substances Data: 946-76-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H5ClN4/c10-7-1-3-8(4-2-7)13-14-9(5-11)6-12/h1-4,13H

Upstream product

• 17333-85-6 4-chlorophenyldiazonium salt 
• 109-77-3 malononitrile 
• 13166-10-4 isopropylidenemalonodinitrile 
• 106-47-8 4-chloro-aniline 
• 20265-96-7 p-chloroaniline hydrochloride 
• 2028-74-2 p-chlorobenzenediazonium chloride 
• 922-64-5 1,1-dicyanoethylene 

Downstream Products

• 74982-78-8 2-[(4-Chloro-phenyl)-ethyl-hydrazono]-malononitrile 
• 1056019-65-8 N,N'-dihydroxy-2-(4-chlorphenylhydrazono)-propanediimidamide 
• 1149376-70-4 4-chlorophenylhydrazono-1H-tetrazol-5-yl-acetonitrile 
• 74982-75-5 5-Amino-2-(4-chloro-phenyl)-3-thioxo-2,3-dihydro-[1,2,4]triazine-6-carbonitrile 

Relevant articles and documents

COMPOUNDS HAVING PSEUDOMONAS ANTI-BIOFILM PROPERTIES

The present invention relates to c-di-GMP lowering chemical compounds having anti- biofilm properties. In particular, the present invention relates to anti-biofilm compounds or salts or tautomers thereof for use in treatment and/or prevention of bacterial biofilm infection in human subjects caused by biofilm-forming bacteria of the genus Pseudomonas, in particular Pseudomonas spp. including P. aeruginosa. Methods of treating such infections in human subjects are contemplated as well. The present inventions further relates to the use of an anti-biofilm compound or a salt or tautomer thereof for dispersing biofilms in industrial water systems.

Synthesis, biological evaluation, and molecular modeling of nitrile-containing compounds: Exploring multiple activities as anti-Alzheimer agents

Based on the monoamine oxidase (MAO) inhibition properties of aminoheterocycles with a carbonitrile group we have carried out a systematic exploration to discover new classes of carbonitriles endowed with dual MAO and AChE inhibitory activities, and Aβ anti-aggregating properties. Eighty-three nitrile-containing compounds, 13 of which are new, were synthesized and evaluated. in vitro screening revealed that 31, a new compound, presented the best lead for trifunctional inhibition against MAO A (0.34 μM), MAO B (0.26 μM), and AChE (52 μM), while 32 exhibited a lead for selective MAO A (0.12 μM) inhibition coupled to AChE (48 μM) inhibition. Computational analysis revealed that the malononitrile group can find an advantageous position with the aromatic cleft and FAD of MAO A or MAO B. However, the total binding energy can be handicapped by an internal penalty caused by twisting of the ligand molecule and subsequent disruption of the conjugation (32 in MAO B compared to the conjugated 31). Conjugation is also important for AChE as well as the hydrophilic character of malononitrile that allows this group to be in close contact with the aqueous environment as seen for 83. Although the effect of 31 and 32 against Aβ1–42, was very weak, the effect of 63 and 65, and of the new compound 75, indicated that these compounds were able to disaggregate Aβ1–42 fibrils. The most effective was 63, a (phenylhydrazinylidene)propanedinitrile derivative that also inhibited MAO A (1.65 μM), making it a potential lead for Alzheimer's disease application.

Computer-aided molecular design of pyrazolotriazines targeting glycogen synthase kinase 3

Numerous studies have highlighted the implications of the glycogen synthase kinase 3 (GSK-3) in several processes associated with Alzheimer’s disease (AD). Therefore, GSK-3 has become a crucial therapeutic target for the treatment of this neurodegenerative disorder. Hereby, we report the design and multistep synthesis of ethyl 4-oxo-pyrazolo[4,3-d][1–3]triazine-7-carboxylates and their biological evaluation as GSK-3 inhibitors. Molecular modelling studies allow us to develop this new scaffold optimising the chemical structure. Potential binding mode determination in the enzyme and the analysis of the key features in the catalytic site are also described. Furthermore, the ability of pyrazolotriazinones to cross the blood–brain barrier (BBB) was evaluated by passive diffusion and those who showed great GSK-3 inhibition and permeation to the central nervous system (CNS) showed neuroprotective properties against tau hyperphosphorylation in a cell-based model. These new brain permeable pyrazolotriazinones may be used for key in vivo studies and may be considered as new leads for further optimisation for the treatment of AD.